Immunovant, Inc. (IMVT) R&D credit carryforward — Quarterly & Annual

Screener

Discontinued — last reported Q4 '20

R&D credit carryforward at other companies

Our Bond, Inc.OBAI

$350K+7.7%

HTF

Heartflow, Inc.HTFL

$7.63M+7.3%

Mineralys Therapeutics, Inc.MLYS

$21.17M+37.6%

HRO

HarrowHROW

$4.79M+111%

Oruka Therapeutics, Inc.ORKA

$5.37M+74.4%

Ondas, Inc.ONDS

$1.17M+55.3%

Segments

By geography

United States$53.7M+37.0%

Other financials

Income statement

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Balance sheet

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Cash flow

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Valuation

Market cap$8.21B+201%

Enterprise value$7.31B+89.7%

Returns & leverage

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The source filing: Immunovant, Inc.’s 10-K, filed June 29, 2020. Open the filing →

Filed: Jun 29, 2020, 8:30 AM EDT
Fiscal year: FY2020
Accession: 0000950123-20-006444